Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Eterna Therapeutics Inc.

Eterna focuses on developing innovative off-the-shelf cellular therapies using iPSC-derived mesenchymal stem cells to target solid tumors. The company claims to enhance T-cell anti-tumor activity while limiting systemic exposure.

COM:ETERNATX